MRI findings in men on active surveillance for prostate cancer: does dutasteride make MRI visible lesions less conspicuous? Results from a placebo-controlled, randomised clinical trial

Francesco Giganti (1) , Caroline M. Moore (1) , Nicola L. Robertson (1) , Neil Mccartan (1) , Charles Jameson (1) , Simon R. J. Bott (2) , Mathias Winkler (3) , Giulio Gambarota (4) , Brandon Whitcher (5) , Ramiro Castro (6) , Mark Emberton (1) , Clare Allen (1) , Alex Kirkham (1)

1 UCLH - University College London Hospitals
2 Frimley Park Hospital
3 Charing Cross Hospital
4 LTSI - Laboratoire Traitement du Signal et de l'Image
5 Department of Mathematics [Imperial College London]
6 GlaxoSmithKline

Mots clés: Placebo; Molecular Imaging; Dutasteride; Diffusion Magnetic Resonance Imaging; Prostatic neoplasms

Domaines: Urologie et Néphrologie; Cancer; Imagerie; Médicaments

Francesco Giganti, Caroline M. Moore, Nicola L. Robertson, Neil Mccartan, Charles Jameson, et al.. MRI findings in men on active surveillance for prostate cancer: does dutasteride make MRI visible lesions less conspicuous? Results from a placebo-controlled, randomised clinical trial. European Radiology, 2017, 27 (11), pp.4767-4774. ⟨10.1007/s00330-017-4858-0⟩. ⟨hal-01624586⟩